MedTrace Logo

Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents

NCT00790816 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2018-02-28

No results posted yet for this study

Summary

This study is designed to provide continued access to lapatinib as monotherapy or as part of a combination regimen to cancer subjects who are currently participating in a phase I trial that has met its study objectives.

Conditions

  • Neoplasms, Breast

Interventions

DRUG

Lapatinib in combination with an anti-cancer agent

Lapatinib in combination with paclitaxel, letrozole, capecitabine, capecitabine/oxaliplatin, gemcitabine, docetaxel, trastuzumab, FOLFOX4, or FOLFIRI

DRUG

Lapatinib

Lapatinib monotherapy

DRUG

Lapatinib in combination with an anti-cancer agent as specified by parent protocol

Lapatinib in combination with an anti-cancer agent as specified by parent protocol

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2016-08-19
Completion
2016-08-19

Countries

  • United States
  • Canada
  • Netherlands
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00790816 on ClinicalTrials.gov